Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers

Xenobiotica

Volumn 40, Issue 11, 2010, Pages 782-789

  Akamine, Yumiko ^a   Miura, Masatomo ^b   Sunagawa, Satoko ^a   Kagaya, Hideaki ^b   Yasui Furukori, Norio ^c   Uno, Tsukasa ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Fexofenadine enantiomer; MRP2; OATP2B1; P glycoprotein; Polymorphism

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FEXOFENADINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 2;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG TRANSPORT; ENANTIOMER; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN POLYMORPHISM;

ADULT; ANTI-ALLERGIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; HUMANS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; STEREOISOMERISM; TERFENADINE; YOUNG ADULT;

EID: 77957956134     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.515318     Document Type: Article

References (27)

1. Andersson T, Weidolf L. (2008). Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 28:263-279.
2. Cascorbi I, Gerlof T, Johne A, Meisel C, Hofmeyer S, Schwab M, Schaefeler E, Eichelbaum M, Brinkmann U, Roots I. (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ter 69:169-174.
3. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
4. Drescher S, Schaefeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF. (2002). MDR1 gene polymor-phisms and disposition of the P-glycoprotein substrate fexofena-dine. Br J Clin Pharmacol 53:526-534.
5. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. (2007). Intestinal drug transporter expression and the impact of grape-fruit juice in humans. Clin Pharmacol Ter 81:362-370.
6. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. (2001). Te efect of rifampin administration on the disposition of fexofena-dine. Clin Pharmacol Ter 69:114-121.
7. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. (2004). Efects of grapefruit juice and orange juice components on P-glycoprotein-and MRP2-mediated drug efux. Br J Pharmacol 143:856-864.
8. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y. (2005). Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33:94-101.
9. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. (2001). Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533.
10. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, Kim RB. (2005). Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280:9610-9617.
11. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. (2008). Investigation of the inhibitory efects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663-669.
12. Miura M. (2006). Enantioselective disposition of lansoprazole and rab-eprazole in human plasma. Yakugaku Zasshi 126:395-402. (Pubitemid 44651288)
13. Miura M, Uno T, Tateishi T, Suzuki T. (2007). Determination of fex-ofenadine enantiomers in human plasma with high-performance liquid chromatography. J Pharm Biomed Anal 43:741-745.
14. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. (2006). Multidrug resistance protein 2 genetic polymorphisms infu-ence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074-1084.
15. Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. (2005). Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602-604.
16. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. (2002). Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ter 302:804-813.
17. Perlof MD, von Moltke LL, Greenblatt DJ. (2002). Fexofenadine trans-port in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 42:1269-1274.
18. Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ. (1998). Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 19:455-463.
19. Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T, Uno T. (2009). Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol 67:535-540.
20. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y (2005). Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33: 1477-1481.
21. Simpson K, Jarvis B. (2000). Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59:301-321.
22. Tanaka H, Imamura N, Oguma N, Shintani T, Tanaka K, Hyodo H, Oda K, Kimura A. (2001). Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-parox-ysmal nocturnal hemoglobinuria syndrome. Int J Hematol 73:206-212.
23. Tateishi T, Miura M, Suzuki T, Uno T. (2008). Te diferent efects of itraconazole on the pharmacokinetics of fexofenadine enantiom-ers. Br J Clin Pharmacol 65:693-700.
24. Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, Raub TJ, Brouwer KL. (2008). Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fex-ofenadine in mice. Drug Metab Dispos 36:61-64.
25. Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y. (2006). Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab Pharmacokinet 21:165-169.
26. Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, Wang W, Shen Y, Zhang M, Zheng S. (2007). MDR1 gene polymorphisms and risk of recur-rence in patients with hepatocellular carcinoma after liver trans-plantation. J Surg Oncol 96:62-68.
27. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG. (2004). A variant 2677A allele of the MDR1 gene afects fexofenadine disposition. Clin Pharmacol Ter 76:418-427.